TABLE I

Permeability of the WT and Mutant P2X7 Receptors to Organic Cations

Receptors
I (pA/pF) KR
RP (mV) NMDG+
RP (mV) NMDG+-KR
RP (mV) NMEA+-KR
WT 122 ± 8 −66.9 ± 0.2 −45.4 ± 2.5b −36.5 ± 0.3 −24.6 ± 0.8b −20.0 ± 0.5 −4.6 ± 1.0b 
T15A 30 ± 3a −68.9 ± 0.4 −53.8 ± 1.2b −36.2 ± 0.8 −36.5 ± 0.5 −18.9 ± 0.7 −17.1 ± 1.1 
T15E 94 ± 10 −54.9 ± 1.2a −53.7 ± 1.5 −22.4 ± 0.7a −21.8 ± 0.9 −14.8 ± 0.7a −12.0 ± 0.5 
T15K 187 ± 45 −35.5 ± 0.9a −36.7 ± 0.6 −19.7 ± 0.6a −17.1 ± 0.6 −14.9 ± 0.5a −11.0 ± 0.6b 
T15W 142 ± 11 −52.6 ± 0.9a −47.4 ± 1.3 −23.0 ± 0.3a −22.4 ± 0.5 −16.4 ± 0.8a −14.4 ± 0.7 
T15V 33 ± 4a −65.3 ± 0.6 −48.5 ± 1.9b −36.1 ± 0.3 −32.1 ± 0.6b −20.6 ± 0.4 −17.5 ± 0.5b 
T15S 47 ± 8a −65.8 ± 0.3 −53.4 ± 0.8b −36.6 ± 0.2 −31.7 ± 1.1b −20.9 ± 0.4 −12.9 ± 1.7b 
K17A 250 ± 25a −65.5 ± 0.4 −45.2 ± 3.6b −35.3 ± 0.2a −23.9 ± 1b −18.2 ± 0.6 −7.4 ± 0.4b 
Δ18 180 ± 21 −50.3 ± 0.9a −47.9 ± 1.2 −28.1 ± 0.6a −28.1 ± 1.1 −17.2 ± 0.4 −15.6 ± 1.1 
Receptors
I (pA/pF) KR
RP (mV) NMDG+
RP (mV) NMDG+-KR
RP (mV) NMEA+-KR
WT 122 ± 8 −66.9 ± 0.2 −45.4 ± 2.5b −36.5 ± 0.3 −24.6 ± 0.8b −20.0 ± 0.5 −4.6 ± 1.0b 
T15A 30 ± 3a −68.9 ± 0.4 −53.8 ± 1.2b −36.2 ± 0.8 −36.5 ± 0.5 −18.9 ± 0.7 −17.1 ± 1.1 
T15E 94 ± 10 −54.9 ± 1.2a −53.7 ± 1.5 −22.4 ± 0.7a −21.8 ± 0.9 −14.8 ± 0.7a −12.0 ± 0.5 
T15K 187 ± 45 −35.5 ± 0.9a −36.7 ± 0.6 −19.7 ± 0.6a −17.1 ± 0.6 −14.9 ± 0.5a −11.0 ± 0.6b 
T15W 142 ± 11 −52.6 ± 0.9a −47.4 ± 1.3 −23.0 ± 0.3a −22.4 ± 0.5 −16.4 ± 0.8a −14.4 ± 0.7 
T15V 33 ± 4a −65.3 ± 0.6 −48.5 ± 1.9b −36.1 ± 0.3 −32.1 ± 0.6b −20.6 ± 0.4 −17.5 ± 0.5b 
T15S 47 ± 8a −65.8 ± 0.3 −53.4 ± 0.8b −36.6 ± 0.2 −31.7 ± 1.1b −20.9 ± 0.4 −12.9 ± 1.7b 
K17A 250 ± 25a −65.5 ± 0.4 −45.2 ± 3.6b −35.3 ± 0.2a −23.9 ± 1b −18.2 ± 0.6 −7.4 ± 0.4b 
Δ18 180 ± 21 −50.3 ± 0.9a −47.9 ± 1.2 −28.1 ± 0.6a −28.1 ± 1.1 −17.2 ± 0.4 −15.6 ± 1.1 

Peak amplitude of current (I) reached during a 4-s agonist application and reversal potential (RP) for WT and mutant receptors bathed in KR, NMDG+, NMDG+-KR, or NMEA+-KR solutions at the beginning (0.75 s; left columns) and end (right columns) of a 40-s application of 100 μM BzATP. Data shown are mean ± SEM values from at least six replicates per mutant.

a

Significant differences between WT and mutant receptors during a 40-s agonist application; P < 0.01.

b

Significant shifts in the reversal potential during a 40-s agonist application; P < 0.01.

or Create an Account

Close Modal
Close Modal